SOURCE: Medical Care Technologies, Inc.

January 22, 2010 07:30 ET

Medical Care Technologies Inc. Completes Tele-Health™ Suite Technology for Congestive Heart Failure

LONDON--(Marketwire - January 22, 2010) - Medical Care Technologies Inc. (OTCBB: MDCE) today announced the completion of Tele-Health™ Suite 6.17 technology for Congestive Heart Failure (CHF).

Using MDCE's remote monitoring Tele-Health™ Suite, CHF home patients answer a range of pertinent health related questions. This is supplemented with medical parameters including blood pressure and weight. Data analysis is performed automatically by Tele-Health™ Suite and then sent and reviewed by a healthcare professional.

A study by the Department of Community and Family Medicine, School of Public Health, Faculty of Medicine, and Chinese University of Hong Kong found that coronary heart disease (CHD) is the second leading cause of cardiovascular deaths in China. CHD accounts for 22% of cardiovascular deaths in urban areas and 13% in rural areas. Although mortality from CHD in China is relatively low compared with Western levels, the burden of CHD has been increasing. This is partly because of a worsening profile of risk factors, such as an increased prevalence of hypertension, hyperlipidaemia, overweight/obesity, diabetes, etc. and partly because of an increase in the aged population.

According to the World Health Organization (WHO) estimates, in 2003, 16.7 million people around the globe die of CVD each year. This is over 29% of all deaths globally. The report: "A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies," 2004 Columbia University, New York concluded that CVD in China will increase by 57% by 2030 as compared to year 2000.

Ning Wu, President of MDCE, stated, "We are extremely pleased to have completed this updated CHF application for our Tele-Health™ Suite. Research has demonstrated that on average, patients managing their CHF via telehealth remote monitoring can reduce their health care system utilization by up to 30%. This translates into substantial savings for both the patient and the healthcare system."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. ( is traded under the symbol MDCE on the OTCBB and is based in London, England. The Company is in the process of moving its portfolio of oil resources into medical care technologies. The products/services that the company hopes to acquire are intended to constitute a healthcare delivery and wellness site, dedicated to helping Asian consumers live healthier, more balanced lives. MDCE is planning to provide advanced connectivity, internationally standardized and secure business technology and information systems to assist the Asian health industry -- physicians, pharmacists, medical institutions, and consumers -- in accessing medical resources, health services, education, wellness and pharmaceutical products throughout Asia. MDCE is planning to distribute and provide services at a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Nutraceuticals. Further information on the Company can be found at and the company's website at

Safe Harbor Statement

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: MDCE's products, services, capabilities, performance, opportunities, development and business outlook, guidance on our future financial results and other projections or measures of our future performance; the amount and timing of the benefits expected from strategic initiatives and acquisitions or from deployment of new or updated technologies, products, services or applications; and other potential sources of additional revenue. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: lack of operating history, transitioning from a development company to an operating company, difficulties in distinguishing MDCE's products and services, ability to deploy MDCE's services and products, market acceptance of our products and services; operational difficulties relating to combining acquired companies and businesses; our ability to form and maintain mutually beneficial relationships with customers and strategic partners; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and healthcare and pharmaceutical industries, and our ability to attract and retain qualified personnel. Other risks and uncertainties may include, but are not limited to: lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the global economy, and compliance with federal and state regulatory requirement. Further information about these matters can be found in our Securities and Exchange Commission filings. We expressly disclaim any intent or obligation to update these forward-looking statements. There can be no assurance that the acquisition of GUC's assets will close. MDCE must issue 57,300,000 shares of its common stock to GUC, or GUC's designees in order to close the acquisition. Accounting for the anticipated cancellation of 57,300,000 shares by Patricia Traczykowski, MDCE will have 98,900,000 shares of its common stock issued and outstanding upon the closing of the acquisition.

Contact Information